Skip to NavigationSkip to content

blood clots

NICE recommends Daiichi’s Lixiana for blood clots

Daiichi Sankyo
Daiichi has earned NICE approval for its newly-launched drug Lixiana

Daiichi Sankyo has won a speedy approval from NICE, after the NHS guidance body approved its newly-launched blood clotting drug Lixiana as a treatment for clots in the legs and lungs.

The NICE decision comes just days after Daiichi launched Lixiana (edoxaban) in the UK, and shortly after the Japanese firm earned European approval for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults and the prevention of stroke and clots in adults with

Daiichi Sankyo launches clotting drug Lixiana in UK

Daiichi image
Daiichi Sankyo's Lixiana is the fourth new anticoagulant to hit the UK market

Daiichi Sankyo’s Lixiana has become the latest pharma offering in the class of newer oral anticoagulants in the UK.

Lixiana (edoxaban) reduces the risk of blood clots in people with atrial fibrillation, which is thought to be the commonest heart rhythm disorder.

Negative overtures persuade Sanofi to withdraw drug filing

sanofi image
Sanofi's HQ in Paris

Sanofi has withdrawn its marketing applications worldwide for its drug Mulsevo.

Designed to stop blood clots in cancer patients receiving chemotherapy for locally-advanced or metastatic solid tumours, the injectable drug had been forecast by analysts to achieve annual sales of €240 million ($295 million).

The French firm says it has taken the decision on Mulsevo (semuloparin sodium) after negative opinions on its benefit/risk balance.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches